G protein-coupled receptor drug discovery
G protein-coupled receptors (GPCRs) are the target of approximately 30% of currently marketed drugs, so understanding their molecular functionality is both clinically and commercially relevant.
The recent clarification of the X-ray and cryogenic electron microscopy structure of GPCRs has opened new research opportunities, which we're strongly pursuing with our Drug Discovery Biology colleagues.
In addition to traditional medicinal chemistry programs around GPCR drug discovery, we work in frontier areas such as allosteric modulators of GPCRs, as well as bitopic and bivalent ligands. The adenosine, dopamine, muscarinic acetylcholine and sphingosine-1-phosphate receptors are the focus of these studies.
Our group consists of experts in medicinal chemistry with a focus on the discovery of new treatments for diseases with unmet medical need
Our group specialises in the design, synthesis and biological evaluation of ligands targeting proteins implicated in mental health disorders and cancer